| Disease | Micro RNA | Tissue/ Cell line | MicroRNA regulation | Pathway | More Details | References |
|---|---|---|---|---|---|---|
| Chronic lymphocytic leukemia | hsa-miR-15a | Peripheral blood | Down | MCL1 pathway | p53 deletion results in a decrease of miR-15a, leads to an increase expression of Mcl-1 in chronic lymphocytic leukemia. | Liu et al., 2014 |
| Chronic lymphocytic leukemia | hsa-miR-16-1 | Peripheral blood | Down | MCL1 pathway | p53 deletion results in a decrease of miR-16-1, leads to an increase expression of Mcl-1 in chronic lymphocytic leukemia. | Liu et al., 2014 |
| Breast cancer | hsa-miR-125b | MCF-7 | Down | Mitochondria-caspase-3 pathway | Combined effect of miR-125b and doxorubicin causes the loss of mitochondrial membrane potential and mitochondria outer membrane permeability. | Xie et al., 2015 |
| Hepatocellular carcinoma | hsa-miR-26b | Hepatocyte | Down | MCL1 pathway | hsa-miR-26b directly targets Mcl-1 mRNA which plays an important role in the sensitization effect of miR-26b on TRAIL-induced apoptosis in HCC. miR-26b/Mcl-1 pathway might act as a sensitizer for chemotherapy. | Jiang et al., 2015 |
| Hepatocellular carcinoma | hsa-miR-193b | Hepatocyte | Down | Caspase 3 pathway | Mcl-1 is the direct target of hsa-miR-193b and overexpression of hsa-miR-193b increased cancer cell sensitivity via caspase dependent apoptosis pathway. | Yin et al., 2015 |
| Cervical cancer | hsa-miR-107 | HeLa, SiHa | Down | ATR/Chk1 pathway | MicroRNA-107 inhibits cervical cancer invasion through activating ATR/Chk1 pathway. | Zhou et al., 2014 |